fda bans compounded semaglutide and tirzepatide moves to remove GLP-1 medications from 503B Bulks List FDA bans compounded weight loss

4,5 GLP-1RAs, approved by the US Food and Drug Administration (FDA) for type 2 diabetes (T2D) treatment in 2017, offer well-documented benefits in reducing cardiovascular and kidney complications

Like GLP-1, it affects hunger and food intake

This finding suggests that QSM detection targeting the dorsolateral SNpc is more specific for the pathological identification of early-stage PD

The Honest Verdict If your doctor is choosing between Saxenda and Zepbound in 2026 and your insurance doesnt favor one over the other, Zepbound is usually the better starting point : weekly dosing, larger expected weight loss, and a real self-pay path through LillyDirect